- Home
- HOTH vs CVKD Comparison
HOTH vs CVKD Comparison
Compare HOTH & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOTH | CVKD |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 17.0M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HOTH | CVKD |
|---|---|---|
| Price | $0.95 | $7.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.50 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 649.7K | 53.5K |
| Earning Date | 11-12-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $6.42 |
| 52 Week High | $2.12 | $22.90 |
Technical Indicators
Market Signals| Indicator | HOTH | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 47.22 |
| Support Level | $1.00 | $7.07 |
| Resistance Level | $1.13 | $8.21 |
| Average True Range (ATR) | 0.07 | 0.57 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 11.96 | 47.68 |
Price Performance
Historical ComparisonAbout HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.